User Profiles Site map description
B
- baron corrz
printer printing blurry at epsonprintersupportpro from Not defined · USA
Except for the one or two times a month when you need to print anything, your printer collects dust. You've tried a variety of HP printer drivers, Canon printer drivers, and another printer offline fix for issues like printer printing blurry suggestions with no luck. Well, guess what, we are here to give you the aid when you can't find anything anywhere. Our expert technician knows printers like the back of their hand and can solve any issues that they might be facing without even breaking a sweat. - Barrie Web Design
Web Designer at PathInteractive from Canada · Barrie
Web Design Barrie Ontario is a WordPress development and website designing agency in Barrie, ON. We are offering effective, unique and innovative digital marketing and web development services. If you want more revenue and grow your business online then you can contact Pathinteractive professionals. We have years of experience and knowledge of web development and SEO. We know the latest trends, technology, and techniques in the internet field. Contact us 705-302-2366 to make beautiful, mobile-friendly and responsive websites. Trust our web design services and talk to us Today. - Barry Halsey
Business Development Manager at Logistics from Moldova, Republic of
My name is Barry Halsey, and I work as a Business Development Manager in a logistics company. LCL (Less than Container Load) Container Shipping consolidates multiple small shipments into one container, optimizing space and cost. LCL Container Shipping is ideal for small to medium-sized shipments, offering cost efficiency, flexibility, and reduced inventory costs. Key players include freight forwarders, shipping lines, and customs brokers. While it can lead to longer transit times and requires precise coordination, LCL Container Shipping remains a practical solution in global logistics, ensuring efficient and cost-effective transport for smaller shipments - Barry Hardy
CEO at Edelweiss Connect from Switzerland · Basel
Dr. Barry Hardy is the Chief Executive Officer (CEO) at Edelweiss Connect where he is leading its team supporting the development of new integrating solutions in industrial safety assessment and the translation of research methods to industrial practice. Example recent commercial developments include the creation of the SaferWorldbyDesign collaboration platform (https://www.saferworldbydesign.com/), and the development of the SaferSkin (https://saferworldbydesign.com/saferskin/) and EdelweissData products (https://saferworldbydesign.com/edelweissdata/). He is currently leading the development of new business partnerships and platforms with Wepredic (www.wepredic.com) and EU-ToxRisk (https://www.eu-toxrisk.eu/). He coordinated the OpenTox project in predictive toxicology and is currently President of the OpenTox Association, founded in 2015 as an international non-profit organisation promoting an open knowledge community approach to new methods in predictive toxicology and the 3Rs principles of the refinement, reduction and replacement of animal experiments. Previously, he led the infrastructure development for the IMI EBiSC stem cell banking project, the eNanoMapper project developing solutions supporting nanotechnology safety assessment, OpenRiskNet infrastructure development supporting risk assessment, and knowledge infrastructure development for ACEnano, NanoCommons and EU-ToxRisk. Dr. Hardy obtained his Ph.D. in 1990 from Syracuse University working in computational science. He was a National Research Fellow at the FDA Center for Biologics and Evaluation, a Hitchings-Elion Fellow at Oxford University and CEO of Virtual Environments International. He was a pioneer in the 1990s in the development of Web technology applied to virtual scientific communities and conferences. He has developed technology solutions for internet-based communications, tutor-supported e-learning, laboratory automation systems, and computational science and informatics. In recent years he has also been active in the field of knowledge management as applied to supporting innovation, communities of practice, and collaboration, with a particular focus on developing new evidence-based methods in predictive toxicology and safety assessment. - Barry McGrawGREEN PRODUCTS CAPITALIZE ON A CRITICAL MARKET TREND Growing sustainability concerns have prompted advocacy for stricter chemical regulations, and both evolving policy and consumer preference have stimulated market shifts toward bio-based raw materials. Soybeans have broad applications across both consumer and industrial spheres, often providing benefits in terms of cost, function, and sustainability.
- Basant City
Solitaire Homes at Basant City from India · Ludhiana, Punjab, India
https://basantcity.com/solitaire-homes/ Basant City Solitaire Homes Ludhiana is one of the most sought-after residential projects in the city. It provides a range of world-class amenities to its residents. It promises to give a luxurious lifestyle to its residents. Invest in Basant City Solitaire Homes Ludhiana and enjoy a life of comfort and convenience. Hurry up and call us now to book your home in the magnificent Basant City Solitaire Homes Ludhiana! - Basil Agrocostea
CEO at Agro Accounting CPA from Brazil · United States
We do Accounting for Artists, Freelancers and Creative Companies. Whether you're in NYC, LA - or anywhere in between, given our safe and easy online platform - check out our affordable prices and free accounting + tax advice. Website: https://www.agroaccounting.com - Basil Britto Xavier, PhDBasil Britto Xavier, Ph.D. in Medical Sciences from the University of Antwerp, Belgium. In addition, he holds a master's degree in Biology from the University of Iceland, Iceland, in Medical Bio-Ethics from KU Leuven, Belgium, Radboud University, The Netherlands, University of Padova, Italy, and Master of Philosophy in Microbiology: MPhil from Bharathidasan University. He holds a postgraduate Diploma in Bioinformatics and a Master's in Microbiology. His next-door research interests focus on antibiotic resistance and microbiome studies. He has over 16 years of experience in microbiology, molecular biology, and more specifically in next-generation sequencing workflows for a second (Illumina) and third-generation technologies (Oxford Nanopore and Pacbio) and the development of pipelines used in advanced genomic, metagenomic, transcriptomic research, and in DNA modifications, all related to clinical perspectives within microbiology. His background in molecular microbiology and bioinformatics has given rise to the conduct of unique translational studies that provide insight into the genetic dynamism of organisms and more specifically into multi-drug-resistant bacteria. The recently discovered plasmid-mediated resistance mechanism to colistin in Belgian livestock farming, (Xavier et al, Eurosurveillance, 2016, much-quoted article and novel van gene (vanP) cluster from Enterococcus faecium. In addition, he participated in the development and optimization of the latest next-generation sequencing technology protocols and developed analysis pipelines to use in advanced genetic, genomic, and metagenomic applications in combination with fundamental microbiology/molecular biological techniques with the objective of answering important questions in clinical microbiology/infectious diseases.
- Basil Hubbard
Associate Professor at University of Toronto from Canada · Toronto, Ontario, Canada
Basil (Baz) Hubbard is an Associate Professor in the Department of Pharmacology and Toxicology at the University of Toronto and an Adjunct Associate Professor in the Department of Pharmacology at the University of Alberta. Hubbard received his Bachelor’s degree in Biochemistry from the University of Ottawa, graduating first in his class. He performed his doctoral training in the lab of David Sinclair at Harvard Medical School. There, he discovered the mechanism by which small-molecules are able to enzymatically activate the SIRT1 longevity factor. He pursued his post-doctoral training at Harvard University in David Liu’s lab, where he worked on improving the specificity of gene editing tools using phage-assisted continuous evolution (PACE). Prof. Hubbard’s research focuses on early-stage drug discovery work, the development of gene editing technologies and other macromolecular therapeutics, and applied synthetic and xenobiology. Hubbard's research has appeared in prestigious journals including Science, Nature Methods, and Nature Communications, amongst others. He holds 6 patents and is the primary inventor behind multiple commercial biotech products, and a co-founder of several biotech startups. In 2019 he was awarded the Canadian Society for Pharmacology and Therapeutics (CSPT) Junior Investigator Award.